IDEAYA Biosciences (IDYA) EBT Margin (2020 - 2026)
IDEAYA Biosciences' EBT Margin came in at -1343.80% for Q3 2026, down 1395.98 percentage points from 52.18% a year earlier but up 36.93 percentage points from the prior quarter.
Powered by 
Analysis
IDEAYA Biosciences (IDYA) EBT Margin (2020 - 2026) Analysis & Trends
Over the trailing twelve months to Sep 30, 2026, IDEAYA Biosciences reported EBT Margin of -1267.38%, down 1170.15 percentage points year-over-year; for FY2025, it was -72.84%, up 4598.23 percentage points from FY2024.
- EBT Margin carries a five-year change of +108.06 percentage points (FY2020 to FY2025).
- Going back by year, EBT Margin was -4671.07% in FY2024 (-4096.22 pp), -574.85% in FY2023 (-452.13 pp), -122.72% in FY2022 (+57.19 pp) and -179.91% in FY2021 (+0.99 pp).
- The five-year range for quarterly EBT Margin is -2059.11% (Q4 2024) to 52.18% (Q3 2025).
- The fastest year-over-year change in EBT Margin over five years came in Q4 2025 (a gain of 1189.59 percentage points), and the weakest in Q3 2026 (a drop of 1395.98 percentage points).
- Business Quant data shows IDYA's EBT Margin at -1380.73% (Q2 2026), -1654.63% (Q1 2026) and -869.53% (Q4 2025) in the three quarters before Q3 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 34.46% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 0.13% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 27.75% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 30.74% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 26.27% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 45.21% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 36.90% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 20.41% |
| 10 | IDEAYA Biosciences | 3.07 Bn | 90.55 Mn | - | -1,343.80% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -1,343.80% |
| Jun 30, 2026 | -1,380.73% |
| Mar 31, 2026 | -1,654.63% |
| Dec 31, 2025 | -869.53% |
| Sep 30, 2025 | 52.18% |
| Dec 31, 2024 | -2,059.11% |
| Dec 31, 2023 | -1,068.77% |
| Sep 30, 2023 | -417.09% |
| Jun 30, 2023 | -922.94% |
| Mar 31, 2023 | -333.49% |
| Dec 31, 2022 | -657.46% |
| Sep 30, 2022 | 2.22% |
| Jun 30, 2022 | -384.53% |
| Mar 31, 2022 | -125.19% |
| Dec 31, 2021 | -620.16% |
| Sep 30, 2021 | -130.49% |
| Jun 30, 2021 | -126.21% |
| Mar 31, 2021 | -126.05% |
| Dec 31, 2020 | -49.95% |
| Sep 30, 2020 | -55.72% |
API Access
IDEAYA Biosciences EBT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebt-margin&ticker=IDYA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebt-margin", "ticker": "IDYA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebt-margin&ticker=IDYA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();